文献速递糖尿病

1型糖尿病中的胰岛素抵抗是血小板高反应性的关键调节因素

Insulin resistance in type 1 diabetes is a key modulator of platelet hyperreactivity.
PubMed 文献 · Diabetologia · 2025-04-30

研究纳入32例1型糖尿病患者,以估算葡萄糖处置率(eGDR)评估胰岛素抵抗,用全血流式细胞术检测血小板活化与抑制反应。1型糖尿病组血小板基线活化标志物表达及刺激后活化均高于健康对照,且对前列环素(PGI2)抑制的敏感性降低;合并晚期胰岛素抵抗者血小板活化更高、对PGI2抑制反应更弱。

要点

  • 1型糖尿病患者血小板基线活化标志物表达升高且刺激后活化增强。
  • 1型糖尿病患者对PGI2抑制血小板的敏感性降低。
  • 合并晚期胰岛素抵抗的1型糖尿病患者血小板活化更高、抑制反应更弱。

核心结论

  • 1型糖尿病血小板呈现适应不良表型:基线活性增加、刺激后过度活化、对抑制反应减弱,胰岛素抵抗似乎进一步驱动这种不良血栓表型,提示胰岛素敏感性降低的1型糖尿病患者血小板驱动的心血管风险增强。

研究设计与样本

  • 研究为DEVELOP研究入组的1型糖尿病患者,共32例,中位年龄24岁(范围18-34岁),男性59%,糖尿病病程14.0±6.3年,HbA1c 65.3±14.0 mmol/mol(8.1%)。
  • 以eGDR评估胰岛素抵抗,eGDR>8 mg kg-1 min-1为胰岛素敏感正常,<6 mg kg-1 min-1为晚期胰岛素抵抗。
  • 采用全血多参数流式细胞术同时检测整合素αIIbβ3(PAC-1结合)、P-选择素(CD62P)和磷脂酰丝氨酸(PS)(Annexin V)三种活化标志物,并用机器学习工具FAUST表征血小板亚群。

主要发现

  • 1型糖尿病组较健康对照血小板三种活化标志物基线平均荧光强度升高:CD62P表达521±246 vs 335±67(p<0.001),PAC-1 370±165 vs 231±88(p=0.011),PS 869±762 vs 294±109(p=0.001)。
  • 血小板刺激后,1型糖尿病组上述标志物活化增强。
  • 1型糖尿病组内,晚期胰岛素抵抗组(eGDR<6 mg kg-1 min-1)较胰岛素敏感正常组(eGDR>8 mg kg-1 min-1)单激动剂刺激后血小板活化增加:CD62P表达29,167±2177 vs 22,829±2535(p<0.001),PAC-1 19,339±11,749 vs 5187±2872(p=0.02)。
  • 1型糖尿病组对PGI2抑制血小板的敏感性低于对照;晚期胰岛素抵抗组与胰岛素敏感正常组在PGI2存在时刺激后CD62P抑制分别为17±11% vs 33±12%(p=0.02),PAC-1为48±17% vs 75±7%(p=0.006),PS暴露为33±12% vs 84±10%(p=0.001)。
  • FAUST分析显示基线状态下晚期胰岛素抵抗组与胰岛素敏感正常组八种血小板亚群分布不同,PGI2抑制后也检测到差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Individuals with type 1 diabetes are at increased cardiovascular risk, particularly in the presence of insulin resistance. A prothrombotic environment is believed to contribute to this risk but thrombotic pathways in type 1 diabetes are only partially understood and the role of platelets is incompletely studied. We hypothesised that platelets from individuals with type 1 diabetes exhibit platelet hyperactivity due to both increased propensity for activation and diminished sensitivity to inhibition, with an amplified maladaptive phenotype in those with insulin resistance. METHODS: Blood samples were obtained from individuals with type 1 diabetes enrolled on the 'Double diabEtes and adVErse cLinical Outcome: identification of mechanistic Pathways' (DEVELOP) study with insulin resistance assessed as estimated glucose disposal rate (eGDR), whereby eGDR >8 or <6 mg kg-1 min-1 indicates normal insulin sensitivity or advanced insulin resistance, respectively. Platelet function was analysed using whole blood multiparameter flow cytometry to simultaneously measure three distinct markers of activation, including integrin αIIbβ3 (PAC-1 binding), P-selectin (CD62P) and phosphatidylserine (PS) (Annexin V). Both activation and inhibition responses of the platelets were investigated, which were subjected to the machine learning tool Full Annotation Shape-constrained Trees (FAUST) to characterise platelet subpopulations. RESULTS: A total of 32 individuals with type 1 diabetes were studied (median age [range] of 24 [18-34] years, 59% male, diabetes duration [mean ± SD] of 14.0 ± 6.3 years and HbA1c of 65.3 ± 14.0 mmol/mol [8.1%]). An increased basal expression, measured as mean fluorescence intensity, of all three platelet activation markers was detected in the type 1 diabetes group compared with healthy control participants (CD62P expression 521 ± 246 vs 335 ± 67; p<0.001, PAC-1 370 ± 165 vs 231 ± 88; p=0.011 and PS 869 ± 762 vs 294 ± 109; p=0.001). Following platelet stimulation, an enhanced activation of these markers was found in the type 1 diabetes group. Within the type 1 diabetes group, those with advanced insulin resistance (eGDR<6 mg kg-1 min-1) showed increased platelet activation compared with individuals with normal insulin sensitivity (eGDR>8 mg kg-1 min-1) with single agonist stimulation CD62P expression (29,167 ± 2177 vs 22,829 ± 2535, p<0.001 and PAC-1 19,339 ± 11,749 and 5187 ± 2872, p=0.02). Moreover, individuals with type 1 diabetes showed reduced sensitivity to platelet inhibition by prostacyclin (PGI2) compared with control participants. Stratification of individuals with type 1 diabetes by insulin resistance demonstrated that in the presence of PGI2, suppression of stimulated CD62P was 17 ± 11% and 33 ± 12% (p=0.02) for advanced insulin resistance and normal insulin sensitivity groups, respectively, with even larger differences demonstrated for PAC-1 (48 ± 17% and 75 ± 7%; p=0.006) and PS exposure (33 ± 12% and 84 ± 10%; p=0.001). Furthermore, FAUST analysis showed that, under basal conditions, there was a different distribution of the eight platelet subpopulations comparing advanced insulin resistance and normal insulin sensitivity groups, with differences also detected following PGI2 inhibition. CONCLUSIONS/INTERPRETATION: Our novel characterisation of platelets in type 1 diabetes shows a maladaptive phenotype with increased basal activity together with hyperactivation following stimulation and diminished responses to inhibition. Insulin resistance appears to further drive this adverse thrombotic phenotype, suggesting an enhanced platelet-driven cardiovascular risk in those with type 1 diabetes and reduced insulin sensitivity.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Sagar RC, Yates DM, Pearson SM, et al. Insulin resistance in type 1 diabetes is a key modulator of platelet hyperreactivity. Diabetologia. 2025. PMID: 40304758. doi:10.1007/s00125-025-06429-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。